Form D · Biotechnology
Unravel Biosciences, Inc.
Medford, MA · CIK 0001876967
Offering snapshot reported Aug 24, 2026 · SEC filing
- Reported sold
- $4.1M Offering amount: $4.5M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 7, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 24, 2026 | Initial | $4,100,000 | No comparison | 2 | SEC filing |
| Mar 9, 2023 | Initial | $500,000 | No comparison | 4 | SEC filing |
| Aug 6, 2021 | Initial | $500,000 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-595175
Source: Form D, filed Aug 24, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lewis Geffen | Executive |
| Donald Ingber | Director |
| Richard Novak | Director, Executive |
| Frederic Vigneault | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
196 Boston Ave., Suite 1000
Medford, MA, 02155
Phone: 510-984-2317
Medford, MA, 02155
Phone: 510-984-2317